^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pumitamig (BNT327)

    i
    Other names: BNT327, BMS986545, PM8002, PM 8002, PM-8002, BNT 327, BNT-327, BMS-986545
    Company:
    BMS, BioNTech
    Drug class:
    PD-L1 inhibitor, VEGF-A inhibitor
    Related drugs:
    2d
    A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) (clinicaltrials.gov)
    P1/2, N=129, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • pumitamig (BNT327)
    2d
    A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) (clinicaltrials.gov)
    P1/2, N=234, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • pumitamig (BNT327)
    3d
    BNT324-01: A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=52, Recruiting, BioNTech SE | N=26 --> 52
    Enrollment change
    |
    pumitamig (BNT327) • BNT324
    9d
    BNT327-02: Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy (clinicaltrials.gov)
    P2, N=83, Active, not recruiting, BioNTech SE | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive
    |
    carboplatin • gemcitabine • paclitaxel • albumin-bound paclitaxel • Halaven (eribulin mesylate) • pumitamig (BNT327)
    10d
    BNT324-01: A clinical study to investigate the efficacy and safety of an investigational combination therapy with BNT324 and BNT327 in patients with advanced lung cancer (2024-520238-31-01)
    P1/2, N=26, Not yet recruiting, BioNTech SE
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    pumitamig (BNT327) • BNT324
    17d
    BNT314-02: A clinical study to test if an investigational treatment called BNT314 when used in combination with another investigational treatment BNT327 and chemotherapy is beneficial and safe for patients with advanced colorectal cancer (2025-521768-36-00)
    P1/2, N=168, Recruiting, BioNTech SE
    New P1/2 trial
    |
    MSI (Microsatellite instability)
    |
    pumitamig (BNT327)
    17d
    BNT326-01: A clinical study to test if an investigational treatment called BNT326 is safe and potentially beneficial when used alone or in combination with other investigational treatments such as BNT327, for people with advanced malignant tumors (2024-517261-16-00)
    P1/2, N=172, Recruiting, BioNTech SE
    New P1/2 trial
    |
    pumitamig (BNT327) • BNT326
    17d
    BNT323-03: A clinical study to find the optimal dose of an investigational treatment called BNT323 when used in combination with another investigational treatment, BNT327, and to test if that combination treatment is safe and beneficial for patients with advanced breast cancer (2024-517979-20-00)
    P1/2, N=95, Not yet recruiting, BioNTech SE
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    trastuzumab pamirtecan (BNT323) • pumitamig (BNT327)
    17d
    BNT326-02: A clinical trial to test if an investigational combination therapy with BNT326 and BNT327 is safe and potentially beneficial for people with advanced non-small cell lung cancer (NSCLC) (2024-519344-32-00)
    P1/2, N=88, Not yet recruiting, BioNTech SE
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • pumitamig (BNT327) • BNT326
    17d
    BNT327-03: Safety and efficacy of BNT327, an investigational therapy, in combination with chemotherapy for patients with untreated small-cell lung cancer (2024-515765-34-00)
    P2/3, N=166, Recruiting, BioNTech SE
    New P2/3 trial
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • etoposide IV • pumitamig (BNT327)
    1m
    ROSETTA GI 204: A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) (clinicaltrials.gov)
    P2/3, N=690, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • 5-fluorouracil • pumitamig (BNT327)
    1m
    A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works in Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P2, N=75, Recruiting, BioNTech SE | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • temozolomide • pumitamig (BNT327)